10 Best Pharma Stocks to Buy for Long Term Growth

5. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders: 64 

Novo Nordisk A/S (NYSE:NVO) is a Denmark-based global healthcare company specializing in the development, manufacturing, and marketing of pharmaceutical products for chronic diseases. Its main areas of interest are managing obesity, diabetes, and uncommon illnesses such as growth abnormalities and hemophilia. With well-known medications, including Ozempic, Wegovy, and NovoRapid, the company is a world leader in insulin and GLP-1 therapy.

With a 26% increase in sales and a 26% increase in operating profit at constant exchange rates, Novo Nordisk A/S (NYSE:NVO) produced impressive financial results in 2024. More than 45 million individuals are now receiving diabetes and obesity medicines from the corporation, an increase of nearly 4 million patients over the previous year. To boost market supply beyond pre-existing CMO contracts from 2026, the company will be able to extend its worldwide fill and finish footprint from 11 to 14 sites after completing the acquisition of three Catalent production sites in December 2024. The corporation’s R&D efforts produced several noteworthy obesity treatment readouts, such as amycretin, semaglutide 7.2 milligrams, and CagriSema.

At constant exchange rates, Novo Nordisk A/S (NYSE:NVO) anticipates sales growth of 16% to 24% in 2025, mostly due to the volume increase of GLP-1-based therapies for the treatment of diabetes and obesity. At constant exchange rates, operating profit is anticipated to increase by 19% to 27%, reflecting ongoing expenditures in commercial, R&D, and other activities. Over 80% of patients pay less than $25 for a prescription, and the firm retains extensive formulary access for Wegovy in the US, covering 55 million obese individuals.